CA
NZ
UK
AU
IND
US
Varex Imaging Corporation (Nasdaq:VREX), a leading designer and manufacturer of X-ray tubes, digital detectors, and imaging components used across medical and industrial applications, surged in pre-market trading after Teledyne Technologies Incorporated announced a definitive agreement to acquire the company for $18.90 per share in …
Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX), a global biotechnology leader best known for its dominant cystic fibrosis franchise including KALYDECO, TRIKAFTA, and newer ALYFTREK, extended a rally that began last week following strong second quarterEarnings. The company reported revenue of $3.33 billion and raised full-year guidance …
AbCelleraBiologicsInc. (Nasdaq:ABCL), a clinical stage biotechnology company that discovers antibody based medicines using a proprietary AI powered platform, surged in pre-market trading after releasing anticipated top line Phase 2 data for ABCL635. The data showed the non hormonal therapy reduced moderate to severe hot …
Moderna, Inc. (Nasdaq:MRNA), a biotechnology company known for pioneering mRNA based medicines including its widely distributed COVID-19 vaccine, traded higher in pre-market activity as investors responded to the FDA's approval of mFLUSIVA. The approval marks the company's first mRNA based seasonal flu vaccine and …
RadNet, Inc. (Nasdaq:RDNT), the largest provider of freestanding outpatient diagnostic imaging services in the United States, traded higher in pre-market activity following a second quarter report that beat expectations on nearly every measure. Revenue grew 25 percent year over year to $622.7 million, ahead …
Sionna Therapeutics, Inc. (Nasdaq:SION), a clinical stage biopharmaceutical company developing medicines that normalize the cystic fibrosis transmembrane conductance regulator protein, saw shares collapse following its second quarter update. The pipeline, which includes NBD1 stabilizers SION-719 and SION-451 alongside CFTR modulators galicaftor, SION-109, and SION-2851, …
Tenax Therapeutics, Inc. (Nasdaq:TENX), a Phase 3 clinical-stage specialty pharmaceutical company focused on cardiopulmonary therapies for unmet needs in the US and Canada, saw shares collapse in pre-market trading. The company's lead candidates, TNX-103 and TNX-102, have completed Phase III trials for pulmonary hypertension …
QuidelOrtho (NASDAQ: QDEL) shares plummeted as management slashed full-year 2026 revenue guidance to $2.52 billion to $2.60 billion and adjusted EPS guidance to $0.65 to $0.90, down significantly from previous ranges.
Galectin Therapeutics (NASDAQ: GALT) executed a debt-to-equity conversion totaling approximately $105.8 million, with Chairman Richard Uihlein exchanging outstanding obligations for 34.4 million common shares at a weighted price of $3.07 each.
Ardelyx (NASDAQ: ARDX) shares faced downward pressure after management downwardly revised its full-year 2026 Ibsrela revenue projections to $350 million to $370 million, falling short of the previous $410 million to $430 million range.
Please wait processing your request...